BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824-1833. [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Hutin YJ, Wiktor SZ. Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses. Gut. 2017;66:2052-2053. [PMID: 27566128 DOI: 10.1136/gutjnl-2016-312636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Laufer N, Ojeda D, Polo ML, Martinez A, Pérez H, Turk G, Cahn P, Zwirner NW, Quarleri J. CD4+ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients. World J Hepatol 2017; 9(25): 1073-1080 [PMID: 28951779 DOI: 10.4254/wjh.v9.i25.1073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Werner JM, Adenugba A, Protzer U. Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC? Transplantation. 2017;101:904-909. [PMID: 27941432 DOI: 10.1097/tp.0000000000001606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
4 Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah'moud MA, Manch R, Mohanty SR, Prabhakar A, Reindollar R, DeMasi R, Slim J, Tandon N, Villadiego S, Naggie S. Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. Open Forum Infect Dis 2017;4:ofw258. [PMID: 28480251 DOI: 10.1093/ofid/ofw258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut. 2018;67:1342-1350. [PMID: 28615303 DOI: 10.1136/gutjnl-2017-313832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
6 Lee AB, Karumberia S, Gilmore A, Williams E, Bruner N, Overton ET, Saag MS, Franco RA. Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness. J Infect Dis 2020;222:S365-75. [PMID: 32877566 DOI: 10.1093/infdis/jiaa207] [Reference Citation Analysis]
7 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
9 Silva LD, Bering T, Rocha GA. The impact of nutrition on quality of life of patients with hepatitis C. Curr Opin Clin Nutr Metab Care 2017;20:420-5. [PMID: 28617708 DOI: 10.1097/MCO.0000000000000396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
10 Velázquez-Moctezuma R, Law M, Bukh J, Prentoe J. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathog 2017;13:e1006214. [PMID: 28231271 DOI: 10.1371/journal.ppat.1006214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
11 Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan TR, Freedman ND. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One 2016;11:e0166036. [PMID: 27832143 DOI: 10.1371/journal.pone.0166036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
13 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P. Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C. PeerJ 2019;7:e7666. [PMID: 31565578 DOI: 10.7717/peerj.7666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Pereira Guedes T, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, Maia L, Moreira T, Manuel Ferreira J, Pedroto I. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. GE Port J Gastroenterol 2020;27:149-59. [PMID: 32509920 DOI: 10.1159/000503074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Gut 2018;67:736-45. [PMID: 28360099 DOI: 10.1136/gutjnl-2016-312577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
16 Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A. Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. Eur J Public Health 2017;27:938-41. [PMID: 28340198 DOI: 10.1093/eurpub/ckx025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Virlogeux V, Pradat P, Hartig-lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres A, Ducerf C, Mabrut J, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 2017;37:1122-7. [DOI: 10.1111/liv.13456] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
18 De Nicola S, Aghemo A. The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. Liver Int 2016;36:791-3. [DOI: 10.1111/liv.13123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
19 Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol 2018;113:1329-38. [PMID: 29523864 DOI: 10.1038/s41395-018-0033-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
20 Mbituyumuremyi A, Van Nuil JI, Umuhire J, Mugabo J, Mwumvaneza M, Makuza JD, Umutesi J, Nsanzimana S, Gupta N. Controlling hepatitis C in Rwanda: a framework for a national response. Bull World Health Organ 2018;96:51-8. [PMID: 29403100 DOI: 10.2471/BLT.16.183772] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Chen B, Ye Q, Zhou K, Wang Y. Adsorption and separation of HCV particles by novel affinity aptamer-functionalized adsorbents. Journal of Chromatography B 2016;1017-1018:174-81. [DOI: 10.1016/j.jchromb.2016.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Hung TC, Jassey A, Liu CH, Lin CJ, Lin CC, Wong SH, Wang JY, Yen MH, Lin LT. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. Phytomedicine 2019;53:62-9. [PMID: 30668413 DOI: 10.1016/j.phymed.2018.09.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
23 Kitagawa K, Nakaoka S, Asai Y, Watashi K, Iwami S. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs. J Theor Biol 2018;448:80-5. [PMID: 29634960 DOI: 10.1016/j.jtbi.2018.04.006] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
24 Abdel-Moneim A, Abood A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients. Clin Exp Hepatol. 2018;4:191-196. [PMID: 30324144 DOI: 10.5114/ceh.2018.78123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
25 Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15:737-746. [PMID: 28696154 DOI: 10.1080/14787210.2017.1354697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
26 Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N, Watanabe M, Wakita T. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016;6:34652. [PMID: 27703205 DOI: 10.1038/srep34652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
27 Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis: Daclatasvir plus asunaprevir in non-HD and HD patients. Hepatol Res 2018;48:746-56. [DOI: 10.1111/hepr.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, El-Bendary M, Zaky S, AbdAllah M, Hassany M, Esmat G, Doss W. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34253123 DOI: 10.1080/14787210.2021.1951230] [Reference Citation Analysis]
30 Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat 2019;26:685-96. [PMID: 30739368 DOI: 10.1111/jvh.13080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. Gastroenterology. 2018;154:1435-1448. [PMID: 29274866 DOI: 10.1053/j.gastro.2017.12.015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
32 Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol 2021;12:726419. [PMID: 34456931 DOI: 10.3389/fimmu.2021.726419] [Reference Citation Analysis]
33 Zhang Y, Boktour MR. Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. Prog Transplant 2019;29:248-53. [PMID: 31146627 DOI: 10.1177/1526924819854481] [Reference Citation Analysis]
34 Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis.   Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Adv Ther 2020; 37(9): 4033-4042. [PMID: 3275482 DOI: 10.1007/s12325-020-01449-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
35 Vernaz N, Girardin F, Goossens N, Brügger U, Riguzzi M, Perrier A, Negro F. Drug Pricing Evolution in Hepatitis C. PLoS One 2016;11:e0157098. [PMID: 27310294 DOI: 10.1371/journal.pone.0157098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
36 Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol 2020;17:533-42. [PMID: 32704164 DOI: 10.1038/s41575-020-0332-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
37 Ayoub HH, Abu-Raddad LJ. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections. BMJ Open 2019;9:e026600. [PMID: 31133586 DOI: 10.1136/bmjopen-2018-026600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
38 Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 2018;5:ofy120. [PMID: 29992173 DOI: 10.1093/ofid/ofy120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
39 Prentoe J, Bukh J. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Front Immunol 2018;9:2146. [PMID: 30319614 DOI: 10.3389/fimmu.2018.02146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
40 Boglione L, Cardellino CS, Cusato J, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. Infect Genet Evol 2017;51:167-72. [PMID: 28315743 DOI: 10.1016/j.meegid.2017.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol. 2020;12:111-116. [PMID: 31929880 DOI: 10.3892/mco.2019.1956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WMS, van Leeuwen DJ; The International Liver Pathology Study Group. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Histopathology 2016;68:953-67. [DOI: 10.1111/his.12957] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
43 Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer 2020;127:45-55. [PMID: 33103243 DOI: 10.1002/cncr.33211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Werner JM, Vermehren J. New HCV Therapies and Liver Transplantation. Transplantation 2016;100:260-1. [PMID: 26813409 DOI: 10.1097/TP.0000000000001092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat 2017;24:936-43. [PMID: 28480525 DOI: 10.1111/jvh.12722] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
46 Aghemo A, Horsmans Y, Bourgeois S, Bondin M, Gschwantler M, Hofer H, Semmo N, Negro F, Zhang Z, Marcinak J, Veitsman E, Hazzan R, Mimidis K, Goulis I, Marques N, Flisiak R, Mazur W, Roncero C, Marra F, Pageaux GP, Asselah T, Lampertico P. Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infect Dis Ther 2021. [PMID: 34125405 DOI: 10.1007/s40121-021-00455-1] [Reference Citation Analysis]
47 Velázquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. J Virol 2019;93:e01909-18. [PMID: 30487284 DOI: 10.1128/JVI.01909-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
48 Stroffolini T, Sagnelli E, Almasio PL, Andriulli A, Smedile A, Pirisi M, Sagnelli C, Russello M, Coppola N, de Luca M, Pisaturo M, Rosina F, Gaeta GB; EPACRON study group. Etiological factors of chronic hepatitis in Italy: A 2014 national survey. Eur J Gastroenterol Hepatol. 2017;29:994-997. [PMID: 28538268 DOI: 10.1097/meg.0000000000000907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Butsashvili M, Gvinjilia L, Kamkamidze G, Metreveli D, Dvali S, Rukhadze T, Gamkrelidze A, Nasrullah M, Shadaker S, Morgan J, Averhoff F. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. BMC Res Notes 2020;13:332. [PMID: 32653020 DOI: 10.1186/s13104-020-05173-4] [Reference Citation Analysis]
50 Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol 2016; 22(22): 5285-5292 [PMID: 27298572 DOI: 10.3748/wjg.v22.i22.5285] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Hung TC, Jassey A, Lin CJ, Liu CH, Lin CC, Yen MH, Lin LT. Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection. Viruses 2018;10:E669. [PMID: 30486350 DOI: 10.3390/v10120669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Ehteshami M, Tao S, Ozturk T, Zhou L, Cho JH, Zhang H, Amiralaei S, Shelton JR, Lu X, Khalil A, Domaoal RA, Stanton RA, Suesserman JE, Lin B, Lee SS, Amblard F, Whitaker T, Coats SJ, Schinazi RF. Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. Antimicrob Agents Chemother 2016;60:4659-69. [PMID: 27216050 DOI: 10.1128/AAC.00318-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
53 Cunha LRD, Vieira DA, Giampietro YG, Gomes AD, Lopes de Faria CL Jr, Freire de Melo F, Teixeira R, Teixeira de Carvalho A, Oliveira LM, Filho OAM, Rocha GA, Maria de Magalhães Queiroz D, Neves FS, Silva LD. Interleukin-10 promoter gene polymorphisms are associated with the first major depressive episode in chronic hepatitis C patients. Clin Res Hepatol Gastroenterol 2019;43:417-26. [PMID: 30591371 DOI: 10.1016/j.clinre.2018.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Zafar U, Hasan A, Aslam B, Khalid Z, Baig MU, Akram S. The Frequency of Hepatitis C and its Risk Factors Among Health Care Providers at Tehsil Headquarter Hospital, Hasilpur, Pakistan. Cureus 2018;10:e3176. [PMID: 30357086 DOI: 10.7759/cureus.3176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Imai H, Kamei H, Onishi Y, Ishizu Y, Ishigami M, Goto H, Ogura Y. Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus. Transplant Proc 2018;50:1431-6. [PMID: 29705278 DOI: 10.1016/j.transproceed.2018.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
56 Hu C, Yuan G, Liu J, Huang H, Ren Y, Li Y, Chen X, Li W, Wu T, Deng H, Peng Y, Zhang YY, Zhou Y. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Can J Gastroenterol Hepatol 2018;2018:3908767. [PMID: 30538973 DOI: 10.1155/2018/3908767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
57 Leggio L, Lee MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med. 2017;130:124-134. [PMID: 27984008 DOI: 10.1016/j.amjmed.2016.10.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
58 Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol 2017;89:1304-8. [PMID: 28079256 DOI: 10.1002/jmv.24766] [Reference Citation Analysis]
59 Kumar S, Barouch-Bentov R, Xiao F, Schor S, Pu S, Biquand E, Lu A, Lindenbach BD, Jacob Y, Demeret C, Einav S. MARCH8 Ubiquitinates the Hepatitis C Virus Nonstructural 2 Protein and Mediates Viral Envelopment. Cell Rep 2019;26:1800-1814.e5. [PMID: 30759391 DOI: 10.1016/j.celrep.2019.01.075] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
60 Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP. The Challenge of Treating Children With Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017;64:851-854. [PMID: 28362694 DOI: 10.1097/mpg.0000000000001589] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
61 Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, Iwami S, Watashi K. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci U S A 2017;114:1922-7. [PMID: 28174263 DOI: 10.1073/pnas.1610197114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
62 Di Marco V, D'Ambrosio R, Bronte F, Saracco G, Lanza AG, Forni G, Poggiali E, Calvaruso V; on behalf ITHACA (Italy for THAalassemia, hepatitis C Advances) Group. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? Dig Liver Dis 2016;48:650-5. [PMID: 27012446 DOI: 10.1016/j.dld.2016.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
63 Ndugga N, Lightbourne TG, Javaherian K, Cabezas J, Verma N, Barritt AS 4th, Bataller R. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open 2017;7:e013620. [PMID: 28336739 DOI: 10.1136/bmjopen-2016-013620] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
64 Roberts-Thomson IC, Lung T. Cost-effective options for the prevention and management of gastrointestinal and liver disease in the Asia-Pacific region. J Gastroenterol Hepatol 2018;33:121-7. [PMID: 28833619 DOI: 10.1111/jgh.13925] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Kuftinec G, Loehfelm T, Corwin M, Durbin-Johnson B, Candido M, Hluhanich R, Sarkar S. De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents. Hepat Oncol 2018;5:HEP06. [PMID: 30302197 DOI: 10.2217/hep-2018-0003] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Olesen CH, Augestad EH, Troise F, Bukh J, Prentoe J. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. PLoS Pathog 2021;17:e1009720. [PMID: 34280245 DOI: 10.1371/journal.ppat.1009720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10:789-798. [PMID: 27443347 DOI: 10.1007/s12072-016-9755-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
68 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]
69 Rhodes T, Lancaster K, Harris M, Treloar C. Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health 2018;29:260-73. [DOI: 10.1080/09581596.2018.1459475] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
70 Wang Y, Lee S, Ha Y, Lam W, Chen SR, Dutschman GE, Gullen EA, Grill SP, Cheng Y, Fürstner A, Francis S, Baker DC, Yang X, Lee KH, Cheng YC. Tylophorine Analogs Allosterically Regulates Heat Shock Cognate Protein 70 And Inhibits Hepatitis C Virus Replication. Sci Rep 2017;7:10037. [PMID: 28855547 DOI: 10.1038/s41598-017-08815-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
71 Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol 2020;72:1112-21. [PMID: 32061651 DOI: 10.1016/j.jhep.2020.01.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
72 Chan H, Hassali MA, Md Said R, Omar H, Abd Mutalib NA, De Rozario FW, Abu Hassan MR. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.113226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Gragnani L, Lorini S, Marri S, Vacchi C, Madia F, Monti M, Ferri C, Zignego AL. Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. Autoimmun Rev 2021;:102923. [PMID: 34419670 DOI: 10.1016/j.autrev.2021.102923] [Reference Citation Analysis]
74 Tai CJ, Jassey A, Liu CH, Tai CJ, Richardson CD, Wong SH, Lin LT. Targeting Autophagy Augments BBR-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. Cells 2020;9:E908. [PMID: 32276448 DOI: 10.3390/cells9040908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
76 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
77 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
78 Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res 2018;150:9-14. [PMID: 29217468 DOI: 10.1016/j.antiviral.2017.12.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
79 Danishwar M, Jamil Z, Khan S, Nakhla M, Ahmad I, Ali MA, Lau DTY. Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. JCM 2022;11:984. [DOI: 10.3390/jcm11040984] [Reference Citation Analysis]
80 Stroffolini T, Chini F, Scognamiglio P, Capobianchi MR, Arcà M, Ippolito G, Girardi E. Temporal trend of hospital discharge for non alcoholic cirrhosis in Lazio Region, Italy 2000-2014. Eur J Intern Med 2016;33:e16-7. [PMID: 27210902 DOI: 10.1016/j.ejim.2016.04.018] [Reference Citation Analysis]
81 Roingeard P, Dreneau J, Meunier JC. Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle. Gut 2017;66:759-61. [PMID: 27811312 DOI: 10.1136/gutjnl-2016-312774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients. Wien Klin Wochenschr 2018;130:105-14. [PMID: 28744597 DOI: 10.1007/s00508-017-1231-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
83 Deuffic-burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? Journal of Hepatology 2017;66:304-12. [DOI: 10.1016/j.jhep.2016.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
84 Matta B, Lee TH, Patel K. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Curr HIV/AIDS Rep 2016;13:279-88. [PMID: 27485838 DOI: 10.1007/s11904-016-0329-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
85 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019; 11(9): 663-677 [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
86 Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep 2019;9:5722. [PMID: 30952914 DOI: 10.1038/s41598-019-42114-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
87 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 2016;65:S109-19. [DOI: 10.1016/j.jhep.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
88 Harris M, Bonnington O, Harrison G, Hickman M, Irving W; HepCATT team. Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study. J Viral Hepat 2018;25:762-70. [PMID: 29369467 DOI: 10.1111/jvh.12869] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
89 Plissonnier ML, Lahlali T, Mehlen P, Parent R. [Hepatitis C, EGFR, cirrhosis and netrin-1: potential implications for HCC onset]. Med Sci (Paris) 2016;32:566-8. [PMID: 27406760 DOI: 10.1051/medsci/20163206013] [Reference Citation Analysis]
90 Aghemo A, Degasperi E, De Nicola S, Bono P, Orlandi A, D’ambrosio R, Soffredini R, Perbellini R, Lunghi G, Colombo M. Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology 2016;14:1331-6. [DOI: 10.1016/j.cgh.2016.03.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
91 Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and Ribavirin Combination Therapy Response in Various Hepatitis C Virus Genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.99625] [Reference Citation Analysis]
92 Cosar AM, Durand CM, Cameron AM, Gurakar A. Hepatitis C following liver transplantation: current approach and future research opportunities. Curr Opin Infect Dis 2016;29:346-52. [PMID: 27191202 DOI: 10.1097/QCO.0000000000000274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Liu CH, Lin CC, Hsu WC, Chung CY, Lin CC, Jassey A, Chang SP, Tai CJ, Tai CJ, Shields J, Richardson CD, Yen MH, Tyrrell DLJ, Lin LT. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut 2017;66:1853-61. [PMID: 27436270 DOI: 10.1136/gutjnl-2016-312019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
94 Gragnani L, Lorini S, Marri S, Basile U, Santarlasci V, Monti M, Madia F, Petraccia L, Stasi C, Marello N, Napodano C, Annunziato F, Zignego AL. Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. Hepatology 2021. [PMID: 33721342 DOI: 10.1002/hep.31804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]